We are collaborating with Bristol-Myers Squibb to design and conduct innovative clinical trials in high-need areas to identify the best novel combinations in cancer immunotherapy. We are working toward a shared goal of accelerating the development of new and better treatment options for cancer patients.
Why It Works:
The collaboration leverages the Parker Institute’s network of the top researchers in cancer immunotherapy, access to cutting-edge technologies to evaluate patient responses, as well as our ability to deeply analyze large amounts of data in our clinical studies. We pair this with BMS’s robust pipeline of leading therapies to turn the most innovative research into clinical trials.
This was the Parker Institute’s first major agreement with a biopharma company. We will continue to collaborate with other industry partners to leverage the global pipeline of immunotherapies to get the best treatments to patients faster.